mutations and complicated kar yotype. It follows a linear evolution in the CLL clone through the recurrent acquisition of CDKN2ANot all people with CLL have to have therapy. Inspite of all new advancements, the iwCLL however suggests watchful observation for patients with asymptomatic condition.86 This suggestion relies on not less than two randomi